Sonidegib Therapeutic Cheat Sheet
Basal cell carcinoma (BCC) is the most common human cancer. When curative surgery and radiotherapy are contraindicated, systemic agents targeting the hedgehog signaling pathway are invaluable options for this subset of adult patients with locally advanced BCC (laBCC). Vismodegib and sonidegib are oral options with similar efficacy and side effect profiles. With the absence of head-to-head comparis …
Basal cell carcinoma (BCC) is the most common human cancer. When curative surgery and radiotherapy are contraindicated, systemic agents targeting the hedgehog signaling pathway are invaluable options for this subset of adult patients with locally advanced BCC (laBCC). Vismodegib and sonidegib are oral options with similar efficacy and side effect profiles. With the absence of head-to-head comparis … 
Ciclopirox is the only hydroxypyridone antifungal agent with a unique mechanism of action differentiating it from other antimycotic agents. Unlike the azole-antifungals which block the sterol synthesis in the fungal cell membrane, ciclopirox functions by chelating cations resulting in the degradation of fungal cells, as well as proposed anti-inflammatory properties. It is available in a variety of … 
Generalized pustular psoriasis (GPP) is a rare, autoinflammatory condition, with acute, severe flares of diffuse sterile pustules and systemic symptoms that can be life-threatening. Historically, cyclosporine, methotrexate, retinoids, and biologics modulating the interleukin-17 (IL-17), IL-23, and tumor necrosis factor α pathways have been used off-label for management.1 Aberrant IL-36 signaling … 
Oxymetazoline is an adrenoreceptor agonist which is FDA-approved for dermatologic conditions including persistent facial erythema in rosacea and blepharoptosis. Functioning primarily as a vasoconstrictor with additional anti-inflammatory properties, oxymetazoline targets the sustained vasodilated state of cutaneous blood vessels in rosacea by inducing vasoconstriction and reducing the persistent f … 
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma … 